Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Methodological standard

Draft certificate-of-analysis minimum data standard

Consultation on the draft standard specifying the minimum data a certificate of analysis must carry before the Institute will treat it as interpretable. The draft classifies each field as critical or recommended and records that a certificate missing a…

Document identifier
CEI-CP-003
Series
Public comment period
Version
1.0
Published
12 Dec 2023
Last reviewed
12 Dec 2023
Next review
12 Dec 2024
Identifier
10.71829/cei.cp.3
Certainty
Not rated
Cycle
2023 Q4
Window
11 Oct 2023 – 08 Nov 2023
Status
Closed
Submissions
13

§1Consultation and window

§1.1Window

Opened
11 October 2023
Closed
8 November 2023
Duration
28 days
Status
Closed — the disposition is published
Document under consultation
Standard CEI-MS-14
Submissions received
13

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Is the classification of any field as critical rather than recommended disproportionate to what a reader needs in order to interpret the figure?
  2. Should the standard require the integration start time for a chromatographic purity figure, given that the same chromatogram can yield materially different purities depending on where integration begins?
  3. Does the standard state clearly enough that a conformant certificate establishes nothing about any batch other than the one tested?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The standard was amended before ratification. Two fields were moved from critical to recommended because no respondent could describe a reading that turned on them, and one field, the integration window, was moved in the opposite direction.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.